외과계중환자실 담당약사의 약물유해반응 예방에 대한 처방중재효과
Effect of Clinical Pharmacist Interventions on Prevention ofAdverse Drug Events in Surgical Intensive Care Unit
1
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Background: A pharmacist’s participation in medical rounds in intensive care unit (ICU) is becoming popular nowadays. In this study, we investigated the effect of pharmacologic intervention by a pharmacist’s participation in medical round in ICU on prevention of adverse drug events (ADEs). Methods: From March 2011 to July 2011, the intervention data were obtained by participating in medical round two or three times a week, and by reviewing electronic medical records of patients admitted to surgical ICU. The incidence, cause, and type of ADEs were noted, respectively. Expected cost avoidance was calculated from interventions, which were considered to be preventive of ADEs. The acceptance rate of pharmacologic interventions was noted. Results: Among 2781 patients, a total of 159 intervention data were collected in 90 patients. Recommendation for drug dosage adjustment or monitoring in patients with potential overdose and sub-therapeutic dose made up 82% of the total interventions. In 8% of interventions, initiation of drug therapy was recommended. 83% of the interventions were accepted and the acceptance rate of interventions within 24 hrs was 58%. The rate of the interventions, which were considered to be preventive of ADEs was 62%. Expected cost reduction obtained by preventing ADEs was 25,867,083￦ during a 5-month period. Conclusions: A pharmacist’s participation in physician rounds in ICU was associated with prevention of ADEs and subsequent reduction of the cost in drug therapy.
Abstract
Background: A pharmacist’s participation in medical rounds in intensive care unit (ICU) is becoming popular nowadays. In this study, we investigated the effect of pharmacologic intervention by a pharmacist’s participation in medical round in ICU on prevention of adverse drug events (ADEs). Methods: From March 2011 to July 2011, the intervention data were obtained by participating in medical round two or three times a week, and by reviewing electronic medical records of patients admitted to surgical ICU. The incidence, cause, and type of ADEs were noted, respectively. Expected cost avoidance was calculated from interventions, which were considered to be preventive of ADEs. The acceptance rate of pharmacologic interventions was noted. Results: Among 2781 patients, a total of 159 intervention data were collected in 90 patients. Recommendation for drug dosage adjustment or monitoring in patients with potential overdose and sub-therapeutic dose made up 82% of the total interventions. In 8% of interventions, initiation of drug therapy was recommended. 83% of the interventions were accepted and the acceptance rate of interventions within 24 hrs was 58%. The rate of the interventions, which were considered to be preventive of ADEs was 62%. Expected cost reduction obtained by preventing ADEs was 25,867,083￦ during a 5-month period. Conclusions: A pharmacist’s participation in physician rounds in ICU was associated with prevention of ADEs and subsequent reduction of the cost in drug therapy.
참고문헌 (41)
- Klopotowska JE, "On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study", Crit Care, 14, pp.R174~ (2010)
- Kopp BJ, "Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist", Am J Health Syst Pharm, 64, pp.2483~2487 (2007)
- MacLaren R, "Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections", Crit Care Med, 36, pp.3184~3189 (2008)
- Mutnick AH, "Cost savings and avoidance from clinical interventions", Am J Health Syst Pharm, 54, pp.392~396 (1997)
- Zaidi ST, "Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital", Pharm World Sci, 25, pp.299~302 (2003)
- Dooley MJ, "A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals", Br J Clin Pharmacol, 57, pp.513~521 (2004)
- de Boer M, "SUREPILL study group: Cost-effectiveness of ward-based pharmacy care in surgical patients: protocol of the SUREPILL (Surgery & Pharmacy In Liaison) study", BMC Health Serv Res, 11, pp.55~ (2011)
- Katona BG, "Effect of a pharmacist's and a nurse's interventions on cost of drug therapy in a medical intensive-care unit", Am J Hosp Pharm, 46, pp.1179~1182 (1989)
- Nesbit TW, "Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model", Am J Health Syst Pharm, 58, pp.784~790 (2001)
- Koo HY, "Effects of adverse drug reactions detected using monitoring program on the length of stay and charges in the hospital setting", 박사, pp.2009
- Cullen DJ, "Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units", Crit Care Med, 25, pp.1289~1297 (1997)
- Kane-Gill S, "Adversedrug- event rates for high-cost and high-use drugs in the intensive care unit", Am J Health Syst Pharm, 63, pp.1876~1881 (2006)
- Leape LL, "Pharmacist participation on physician rounds and adverse drug events in the intensive care unit", JAMA, 282, pp.267~270 (1999)
- Kane-Gill SL, "Analysis of risk factors for adverse drug events in critically ill patients", Crit Care Med, 40, pp.823~828 (2012)
- Raber A, "Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom", Ther Clin Risk Manag, 3, pp.225~230 (2007)
- McHardy GG, "A multicenter, double-blind trial of sucralfate and placebo in duodenal ulcer", J Clin Gastroenterol, 3(Suppl 2), pp.147~152 (1981)
- Arcieri GM, "Safety of intravenous ciprofloxacin", A review. Am J Med, 87, pp.92S~97S (1989)
- Calandra GB, "The safety profile of imipenem", cilastatin: worldwide clinical experience based on 3470 patients, 1986, pp.18(Suppl E), 193~202
- Herzig SJ, "Acid-suppressive medication use and the risk for hospital-acquired pneumonia", JAMA, 301, pp.2120~2128 (2009)
- Ward A, "Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use", Drugs, 30, pp.382~426 (1985)
- Smith CR, "Cefotaxime and cephalosporins: adverse reactions in perspective", Rev Infect Dis, 4(Suppl), pp.S481~S488 (1982)
- Goldstein EJ, "Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety", Clin Infect Dis, 23(Suppl 1), pp.S25~S30 (1996)
- Agura ED, "The use of ranitidine in bone marrow transplantation. A review of 223 cases", Transplantation, 46, pp.53~56 (1988)
- Antman E, "Nifedipine therapy for coronary-artery spasm. Experience in 127 patients", N Engl J Med, 302, pp.1269~1273 (1980)
- Gatell JM, "Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin", Antimicrob Agents Chemother, 23, pp.897~901 (1983)
- Lodise TP, "Relationship between initial vancomycin concentrationtime profile and nephrotoxicity among hospitalized patients", Clin Infect Dis, 49, pp.507~514 (2009)
- Lerner SA, "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin", Am J Med, 80, pp.98~104 (1986)
- Klugman KP, "Meropenem Meningitis Study Group", Antimicrob Agents Chemother, 39, pp.1140~1146 (1995)
- Ueda T, "Evaluation of teicoplanin dosing designs to achieve a new target trough concentration", J Infect Chemother, 18, pp.296~302 (2012)
- Hansen ML, "Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation", Arch Intern Med, 170, pp.1433~1441 (2010)
- Gilvert DN, "The sanford guide to antimicrobial therapy", pp.87~ (2011), Antimicrobial Therapy Inc
- Tzivoni D, "Suppression of ventricular arrhythmias by magnesium", Am J Cardiol, 65, pp.1397~1399 (1990)
- Van den Berghe G, "Intensive insulin therapy in critically ill patients", N Engl J Med, 345, pp.1359~1367 (2001)
- Btaiche IF, "Metabolic complications of parenteral nutrition in adults, Part 2", Am J Health Syst Pharm, 61, pp.2050~2057 (2004)
- Hiesmayr M, "Nutrition risk assessment in the ICU", Curr Opin Clin Nutr Metab Care, 15, pp.174~180 (2012)
- Powell-Jackson PR, "Hepatotoxicity to sodium valproate: a review", Gut, 25, pp.673~681 (1984)
- Gilvert DN, "The sanford guide to antimicrobial therapy", pp.90~ (2011), Antimicrobial Therapy Inc
- Kelly DA, "Liver complications of pediatric parenteral nutrition-- epidemiology", Nutrition, 14, pp.153~157 (1998)
- Levin AS, "Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii", Clin Infect Dis, 28, pp.1008~1011 (1999)
- Salzberger B, "Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome", Blood, 90, pp.2502~2508 (1997)
- Henkin RI, "An open-label controlled trial of theophylline for treatment of patients with hyposmia", Am J Med Sci, 337, pp.396~406 (2009)